QSEIF · QSEIF: The new pathogen, DNA and immunological testing platform

iMiCROQ aims to bring to the market the first integrated platform for pathogen, immumological and PCR testing speciallydesigned to cover the whole needs at farm level, internal control laboratories, food processors and point-of-care infectiousdisease testing. Thanks to its affordability, QSEIF will allow from SMEs to large companies to improve their biosafety andinternal microbiology control to fulfil their requirements from ISO 22000, BRC or IFS certifications, while reducing the needsin laboratory space, the investment, the test cost and man-hour involvement thanks to higher automation. Another importantbreakthrough in the immunological sector is that QSEIF provides 1-2 orders of magnitude lower limit of detection, less timeand better dynamic range than current reference test ELISA. We envision three important applications of this disruptiveplatform in the areas of: (1) Food Safety; (2) Vaccination Control; (3) Immunoassays for human and animal diagnosis. Wewill reach end-users from all these sectors according to different commercial strategies that have been tailored to suit eachtype of customer.The main objective of this project is to increase the technical maturity of the platform and to validate its performance andoperability in operational environment with different end-users. After this 24 months project, we will lauch QSEIF to themarket with the aim of becoming an international reference in the diagnostic market. The viability of the technological,regulatory, market and financial aspects of the QSEIF innovation project were assessed through a feasibility analysis carriedout in SME Instrument Phase I. From the analysis, we expect to install 717 devices that would perform 5.2M tests in a fiveyear period. By then, QSEIF platform will bring an accumulated Net Profit of 5,32M€ by 2024. It is expected that sales ofQSEIF will represent 40% of the company’s total revenue in 2021, growing to 88% by 2024.